JO2526B1 - substituted 1,4-di-piperidin-4-yl-piperizine derivatives and their use as neurokinin antagonists - Google Patents

substituted 1,4-di-piperidin-4-yl-piperizine derivatives and their use as neurokinin antagonists

Info

Publication number
JO2526B1
JO2526B1 JO2003131A JOP20030131A JO2526B1 JO 2526 B1 JO2526 B1 JO 2526B1 JO 2003131 A JO2003131 A JO 2003131A JO P20030131 A JOP20030131 A JO P20030131A JO 2526 B1 JO2526 B1 JO 2526B1
Authority
JO
Jordan
Prior art keywords
disorders
neurokinin
diseases
piperidin
emesis
Prior art date
Application number
JO2003131A
Other languages
Arabic (ar)
Inventor
ستاتيسلاس مارسيلا ديس جاستون
ايميل ماريا فان روسبرويك ايف
اليزابيث لينارتس جوزيف
كريستيان البرت جيزلاين دي بويك بينوا
ماريا سومين فرانسوا
ادوارد جانسينس فرانس
Original Assignee
ايلانكو انيمال هيلث ايرلند ليميتد
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ايلانكو انيمال هيلث ايرلند ليميتد filed Critical ايلانكو انيمال هيلث ايرلند ليميتد
Application granted granted Critical
Publication of JO2526B1 publication Critical patent/JO2526B1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention concerns substituted 1,4-di-piperidin-4-yl-piperazine derivatives having neurokinin antagonistic activity, in particular NK1 antagonistic activity, their preparation, compositions comprising them and their use as a medicine, in particular for the treatment of emesis, anxiety, depression, pain, pancreatitis and IBS. The compounds according to the invention can be represented by general Formula (I), and comprises also the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the N-oxide form thereof and prodrugs thereof, wherein all substituents are defined as in Claim 1. In view of their capability to antagonize the actions of neurokinins by blocking the neurokinin receptors, and in particular antagonizing the actions of substance P by blocking the NK1 receptor, the compounds according to the invention are useful as a medicine, in particular in the prophylactic and therapeutic treatment of neurokinin-mediated conditions, such as, for instance CNS disorders, in particular depression, anxiety disorders, stress-related disorders, sleep disorders, cognitive disorders, personality disorders, schizoaffective disorders, eating disorders, neurodegenerative diseases, addiction disorders, mood disorders, sexual dysfunction, pain and other CNS-related conditions; inflammation; allergic disorders; emesis; gastrointestinal disorders, in particular irritable bowel syndrome (IBS); skin disorders; vasospastic diseases; fibrosing and collagen diseases; disorders related to immune enhancement or suppression and rheumatic diseases and body weight control
JO2003131A 2002-10-08 2003-10-05 substituted 1,4-di-piperidin-4-yl-piperizine derivatives and their use as neurokinin antagonists JO2526B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP0211328 2002-10-08
EP0214836 2002-12-23

Publications (1)

Publication Number Publication Date
JO2526B1 true JO2526B1 (en) 2010-03-17

Family

ID=48040996

Family Applications (1)

Application Number Title Priority Date Filing Date
JO2003131A JO2526B1 (en) 2002-10-08 2003-10-05 substituted 1,4-di-piperidin-4-yl-piperizine derivatives and their use as neurokinin antagonists

Country Status (1)

Country Link
JO (1) JO2526B1 (en)

Similar Documents

Publication Publication Date Title
MY141736A (en) Substituted 1,4-di-piperidin-4-yi-piperazine derivatives and their use as neurokinin antagonists
TW200500359A (en) Substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
DE60312042D1 (en) SUBSTITUTED 1-PIPERIDIN-4-YL-4-AZETIDIN-3-YL-PIPERAZINE DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS
MX2007007472A (en) Triazolone, tetrazolone and imidazolone derivatives for use as alpha-2c adrenoreceptor antagonists.
MX2009005507A (en) Spiro-piperidine derivatives.
HUP0303751A2 (en) Use of n-phenyl-2-pyrimidineamine derivatives for preparation of pharmaceutical compositions suitable for treating mast cell-based diseases like allergic disorders
NO331173B1 (en) Substituted 1-piperidin-3-yl-4-piperidin-4-yl-piperazine derivatives and their use as neurokinin antagonists.
WO2008077810A3 (en) Spiro-piperidine derivatives
ATE457985T1 (en) SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS MEDICINAL PRODUCTS
MX2009005504A (en) Spiro-piperidine derivatives as via receptor antagonists.
TW200833696A (en) Spiro-piperidine derivatives
JO2526B1 (en) substituted 1,4-di-piperidin-4-yl-piperizine derivatives and their use as neurokinin antagonists
MXPA05003778A (en) Substituted 1,4-di-piperidin-4-yl-piperazine derivatives and their use as neurokinin antagonists.
HUP0300694A2 (en) Indole derivatives as mcp-1 receptor antagonists, their use, process for their preparation and pharmaceutical compositions containing them
CA2509090A1 (en) Substituted 4-(4-piperidin-4-yl-piperazin-1-yl)-azepane derivatives and their use as neurokinin antagonists
IL192240A0 (en) Substituted pyrazinone derivatives as alpha2c-adrenoreceptor antagonists
NO20084819L (en) Substituted pyrazinone derivatives for use as a medicine
BR0317667A (en) Substituted 1-piperidin-3-yl-4-piperidin-4-yl-piperazine derivatives and their use as neurokinin antagonists
TH78668A (en) The 1-piperidin-4-il-4-pirrelidin-3-il-piperine derivatives are replaced, and their use is an antagonist of Ni Warokinin
TH68224A (en) The 1-piperidin-3-il-4-piperidin-4-il-piperazine derivative is replaced. And the use of those substances as neurokinins and antagonists
TH105523A (en) 1,4-di-piperidin-4-il-piperazine derivative Replaced And the use of those substances as antiretroviral agents
TH105523B (en) 1,4-di-piperidin-4-il-piperazine derivative Which were replaced and the use of those substances as antiretroviral agents